Phosphatidylcholine controlled release - Lipid Therapeutics

Drug Profile

Phosphatidylcholine controlled release - Lipid Therapeutics

Alternative Names: LT-02; Phosphatidyl choline; Retarded release phosphatidylcholine

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Heidelberg
  • Developer Dr Falk Pharma; Lipid Therapeutics
  • Class Antiulcers; Cytoprotectives; Glycerophospholipids; Lipids
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ulcerative colitis

Most Recent Events

  • 07 Feb 2017 Dr. Falk Pharma terminates a phase-III clinical trial due to IDMC recommendation in Ulcerative colitis (Treatment-resistant, Adjunctive treatment) in Austria, Belgium, the Czech Republic, Germany, Hungary, Latvia, Lithuania, Netherlands, Slovakia and Poland (PO) (NCT02142725)
  • 01 Jul 2016 Phase-III clinical trials in Ulcerative colitis (Treatment-resistant, Adjunctive treatment) in USA (PO) (NCT02849951)
  • 16 Sep 2015 Phosphatidylcholine controlled-release licensed to Nestle Health Science worldwide (excluding Australia and Europe)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top